Hoth Therapeutics Obtains Full Licensing Rights for BioLexa Platform, Atopic Dermatitis Treatment

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders

Hoth Therapeutics, Inc. has obtained exclusive worldwide licensing rights to the BioLexa Platform, a proprietary, patented antimicrobial therapy focused on treating atopic dermatitis. 

This agreement serves as an extension to the previously executed sublicense agreement for the compound with Chelexa Biosciences, Inc.

"Management is pleased to fully own global licensing rights for the BioLexa Platform," says Robb Knie, CEO of Hoth Therapeutics, in a news release.

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH's pipeline is focused on atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has recently entered into a Joint Development Agreement to further the development of vaccine prospects to prevent, intercept or treat the Coronavirus (COVID-19) based upon VaxCelerate, a self-assembling vaccine (SAV) platform exclusively licensed by Voltron from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital.